WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with...
NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- via BioMedWire: — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in...
Cretostimogene demonstrated HG-EFS at 3- 6- and 9-months of 95.7%, 84.6% and 80.4%, respectively, in HR BCG UR Ta/T1 Disease...
AI-Driven Risk Prediction for Breast, Prostate and Pancreatic CancersTOKYO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- A.D.A.M. Innovations Co. (Japanese Name:...
A leader in medically supervised weight management, proudly announces a major milestone: more than 10 million pounds lost collectively by...
A meso–macroporous hydrogel enables rapid, scalable extracellular vesicle isolation from diverse biofluids without preprocessing stepsSEOUL, South Korea, Dec. 4, 2025...
IRVING, Texas, Dec. 4, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine...
NEW YORK, Dec. 4, 2025 /PRNewswire/ -- PreciseDx, the leading innovator behind PreciseBreast, a novel AI digital pathology test, announces the...
COLUMBUS, Ohio and NEW YORK, Dec. 4, 2025 /PRNewswire/ -- Paradigm Health, the technology company rebuilding the clinical research ecosystem,...
Partnership creates the largest oncology research network in the United States, enabling clinical trials to reach rural and community-based practices...
Scientific and medical presence at ASH underscores Parexel’s proven expertise at premier event for classical and malignant hematologyRALEIGH, N.C., Dec....
Joint Research Team Focusing on Impact of PRP Reversal of EMT Pathways as Central RoleMELBOURNE, Australia, Dec. 04, 2025 (GLOBE...
SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology...
AUSTIN, Texas, Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Chronic illnesses and rare disorders among older Americans represent...
Drawing on over 50 years of drug development experience, Dr. Hausman strengthens the Company’s mission to combat cancer and other...
FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Syncromune®, Inc., a clinical-stage biopharmaceutical company...
NEW HAVEN, Conn., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Precipio, Inc. reports that the Company recently identified a single, limited...
SAN DIEGO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- ViroMissile, Inc., a cancer immunotherapy company pioneering the IDOV™ (Intravenously Deliverable Oncolytic...
NAMPT inhibitor RPT1G demonstrated favorable safety and significant target engagement in first-in-human study Company to present Trial in Progress design...
– Data demonstrate superior efficacy compared to ruxolitinib, an approved type I JAK2 inhibitor, including reductions in mutant allele burden and...